Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
35.00 x 5 35.60 x 1
Post-market by (Cboe BZX)
35.59 -0.60 (-1.66%) 04/21/25 [NASDAQ]
35.00 x 5 35.60 x 1
Post-market 35.59 unch (unch) 16:33 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
35.34
Day High
36.56
Open 36.06
Previous Close 36.19 36.19
Volume 1,950,200 1,950,200
Avg Vol 2,524,265 2,524,265
Stochastic %K 75.21% 75.21%
Weighted Alpha +45.42 +45.42
5-Day Change +0.28 (+0.79%) +0.28 (+0.79%)
52-Week Range 20.14 - 40.02 20.14 - 40.02
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,128,894
  • Shares Outstanding, K 279,881
  • Annual Sales, $ 2,169 M
  • Annual Income, $ 521,270 K
  • EBIT $ 605 M
  • EBITDA $ 633 M
  • 60-Month Beta 0.57
  • Price/Sales 4.67
  • Price/Cash Flow 18.77
  • Price/Book 4.60

Options Overview Details

View History
  • Implied Volatility 50.72% ( +5.45%)
  • Historical Volatility 33.49%
  • IV Percentile 78%
  • IV Rank 59.79%
  • IV High 72.42% on 08/05/24
  • IV Low 18.44% on 11/08/24
  • Put/Call Vol Ratio 0.83
  • Today's Volume 621
  • Volume Avg (30-Day) 1,216
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 30,931
  • Open Int (30-Day) 38,126

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.34
  • Number of Estimates 7
  • High Estimate 0.42
  • Low Estimate 0.27
  • Prior Year 0.12
  • Growth Rate Est. (year over year) +183.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.38 +9.91%
on 04/09/25
Period Open: 36.96
38.41 -7.34%
on 03/26/25
-1.37 (-3.71%)
since 03/21/25
3-Month
31.90 +11.57%
on 01/24/25
Period Open: 36.43
40.02 -11.07%
on 03/10/25
-0.84 (-2.31%)
since 01/21/25
52-Week
20.14 +76.71%
on 05/29/24
Period Open: 22.52
40.02 -11.07%
on 03/10/25
+13.07 (+58.04%)
since 04/19/24

Most Recent Stories

More News
Private Sector Steps Up in Cancer Research as Federal Support Wavers

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH), questions...

ONCY : 0.5750 (+2.50%)
SMMT : 25.22 (+2.48%)
CADL : 4.51 (-1.31%)
IMTX : 4.24 (-0.47%)
EXEL : 35.59 (-1.66%)
ONC.TO : 0.79 (+2.60%)
The Smartest Biotech Stocks to Buy With $50

One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share prices,...

VKTX : 23.72 (-0.92%)
LLY : 818.02 (-2.61%)
EXEL : 35.59 (-1.66%)
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib).The regulatory body approved Cabometyx for the treatment of adult and pediatric patients...

BAYRY : 5.9100 (-1.83%)
NVO : 58.33 (+0.43%)
EXEL : 35.59 (-1.66%)
BMY : 48.94 (-0.59%)
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe. The company's...

MRK : 77.85 (-0.19%)
EXEL : 35.59 (-1.66%)
BMY : 48.94 (-0.59%)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.5750 (+2.50%)
EXEL : 35.59 (-1.66%)
ONC.TO : 0.79 (+2.60%)
ALXO : 0.5662 (+2.95%)
CRDF : 2.82 (-1.05%)
VSTM : 6.21 (+8.19%)
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

For Immediate ReleaseChicago, IL – February 26, 2025 – Stocks in this week’s article are Gilead Sciences GILD, Exelixis EXEL, Synchrony Financial SYF and Molson Coors TAP.4 PEG-Based GARP Stocks...

SYF : 47.23 (-1.34%)
TAP : 57.93 (-1.40%)
EXEL : 35.59 (-1.66%)
GILD : 104.33 (-0.20%)
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

The new year has been turbulent so far for the equity market, with geopolitical tensions and trade policies playing a significant role in shaping investor sentiment. Trump's tariff policies have not only...

SYF : 47.23 (-1.34%)
TAP : 57.93 (-1.40%)
EXEL : 35.59 (-1.66%)
GILD : 104.33 (-0.20%)
Why Exelixis Stock Trounced the Market on Thursday

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push...

EXEL : 35.59 (-1.66%)
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

GRAL : 26.42 (-2.15%)
ADMA : 19.64 (-7.84%)
EXEL : 35.59 (-1.66%)
GLYC : 0.2200 (-1.35%)
MBRX : 0.9502 (+8.61%)
Exelixis (EXEL) Q4 2024 Earnings Call Transcript

EXEL earnings call for the period ending December 31, 2024.

EXEL : 35.59 (-1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 37.54
2nd Resistance Point 37.05
1st Resistance Point 36.32
Last Price 35.59
1st Support Level 35.10
2nd Support Level 34.61
3rd Support Level 33.88

See More

52-Week High 40.02
Last Price 35.59
Fibonacci 61.8% 32.43
Fibonacci 50% 30.08
Fibonacci 38.2% 27.73
52-Week Low 20.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro